← brief for 2026-10-25 · Slowing decline

Empagliflozin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Randomized Controlled Trial.

Article B Peer reviewed Small trial

Key takeaways

A small trial tested a diabetes drug called empagliflozin in people with polycystic kidney disease. The study ran for 12 months and found the drug was safe to use. However, the drug did not slow the growth of the kidneys. It also did not improve how well the kidneys filtered blood.

Who did this work

Seliger SL · Gitomer B · You Z · Wang W · Ostrow A · Andrews E · Diggs C · George D · West M · Nowak KL · Watnick T · Chonchol M

Source

Article · PubMed, the drug frontier · 2026 Oct 24
https://pubmed.ncbi.nlm.nih.gov/42925875/